Get the Stockscreener App
78.25
0.95%
0.74
After Hours:
78.25
Apogee Therapeutics Inc stock is traded at $78.25, with a volume of 1.70M.
It is up +0.95% in the last 24 hours and up +1.95% over the past month.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
See More
Previous Close:
$77.51
Open:
$75
24h Volume:
1.70M
Relative Volume:
1.93
Market Cap:
$5.35B
Revenue:
-
Net Income/Loss:
$-146.66M
P/E Ratio:
-28.41
EPS:
-2.7541
Net Cash Flow:
$-133.21M
1W Performance:
+3.29%
1M Performance:
+1.95%
6M Performance:
+64.88%
1Y Performance:
+62.04%
1-Day Range:
$72.87
$80.22
1-Week Range:
$72.56
$80.22
52-Week Range:
$26.20
$80.99
Apogee Therapeutics Inc Stock (APGE) Company Profile
Name
Apogee Therapeutics Inc
Sector
Industry
Phone
650-394-5230
Address
221 CRESCENT ST., WALTHAM
Compare APGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
78.25 | 5.30B | 0 | -146.66M | -133.21M | -2.7541 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Initiated | Stephens | Overweight |
| Dec-10-25 | Initiated | Deutsche Bank | Buy |
| Nov-03-25 | Initiated | Craig Hallum | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Sep-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-07-25 | Reiterated | BTIG Research | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Nov-25-24 | Initiated | Canaccord Genuity | Buy |
| May-10-24 | Initiated | BofA Securities | Buy |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | Guggenheim | Buy |
| Aug-08-23 | Initiated | Jefferies | Buy |
| Aug-08-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
| Aug-08-23 | Initiated | Wedbush | Outperform |
View All
Apogee Therapeutics Inc Stock (APGE) Latest News
One Shot, Six Months of Asthma Relief? Apogee Drug Shows Strong, Long-Lasting Effect In Trial - Benzinga
Apogee Therapeutics (NASDAQ:APGE) Shares Gap DownWhat's Next? - MarketBeat
Apogee Therapeutics Shares Interim Asthma Data Showing Durable FeNO Drop With APG777 Single Dose - MarketBeat
Apogee Therapeutics stock price target raised to $137 by BTIG on asthma data - Investing.com
Apogee Therapeutics stock maintains Outperform rating at RBC on asthma data - Investing.com
Apogee Therapeutics stock falls after asthma trial data By Investing.com - Investing.com India
Apogee Therapeutics Announces Positive Interim Data from Phase 1b Trial of Zumilokibart - TradingView — Track All Markets
Apogee Therapeutics Reports Positive Phase 1b Data For Zumilokibart In Mild-to-moderate Asthma - Nasdaq
Apogee Therapeutics rises as asthma drug shows promise in early trial - TradingView — Track All Markets
Apogee Therapeutics Reports Positive Phase 1b Interim Results for Zumilokibart (APG777) in Mild-to-Moderate Asthma and Highlights 2026 Development Milestones - Quiver Quantitative
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook - GlobeNewswire Inc.
Apogee Therapeutics to report interim asthma trial results - Investing.com India
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 - The Manila Times
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $128.00 - MarketBeat
(APGE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Apogee Therapeutics (APGE) Stock Analysis Report | Financials & Insights - Benzinga
Is Apogee Therapeutics Inc a good long term investmentDay Trading Setups & High Return Trading Portfolio - earlytimes.in
Apogee Therapeutics Inc. (NASDAQ:APGE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Apogee Therapeutics Inc (NASDAQ:APGE) Nasdaq today Early Biotech Stage - Kalkine Media
Apogee Therapeutics Earnings Notes - Trefis
Analysts Are Bullish on These Healthcare Stocks: Apogee Therapeutics (APGE), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Apogee Therapeutics stock falls after asthma trial data - Investing.com
BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook By Investing.com - Investing.com South Africa
BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook - Investing.com Australia
Value Recap: What technical signals suggest for Apogee Therapeutics Inc. stockMarket Activity Report & Safe Entry Zone Identification - moha.gov.vn
Henderson, Apogee Therapeutics CFO, sells $120k in stock - Investing.com
Apogee Therapeutics CFO Sells 1,500 Shares - TradingView — Track All Markets
Henderson, Apogee Therapeutics CFO, sells $120k in stock By Investing.com - Investing.com Canada
Will Apogee Therapeutics Inc. stock benefit from AI adoption2025 Winners & Losers & Weekly Top Performers Watchlists - Улправда
Apogee Therapeutics (APGE) Gets a Buy from Bank of America Securities - The Globe and Mail
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
Apogee Therapeutics stock hits all-time high of 78.19 USD - Investing.com
Apogee Therapeutics stock hits all-time high of 78.19 USD By Investing.com - Investing.com Nigeria
Apogee Therapeutics (NASDAQ:APGE) Hits New 12-Month HighWhat's Next? - MarketBeat
Is Apogee Therapeutics Inc. stock a safe investment in uncertain markets2025 Winners & Losers & Safe Capital Growth Tips - DonanımHaber
Apogee Therapeutics (NASDAQ:APGE) Rating Increased to Strong-Buy at Stephens - MarketBeat
Market Outlook: Will Apogee Therapeutics Inc. stock benefit from AI adoptionWeekly Market Summary & Weekly Return Optimization Alerts - ulpravda.ru
Will Apogee Therapeutics Inc. stock gain from lower inflation2025 Buyback Activity & Smart Investment Allocation Insights - Улправда
Trend Recap: What insider trading reveals about Apogee Therapeutics Inc. stockMarket Movers & Fast Exit and Entry Strategy Plans - Улправда
What insider trading reveals about Apogee Therapeutics Inc. stockQuarterly Trade Summary & Technical Analysis for Trade Confirmation - Улправда
What dividend safety score for Apogee Therapeutics Inc. stockWeekly Trade Report & Risk Managed Investment Entry Signals - ulpravda.ru
How Apogee Therapeutics Inc. stock benefits from global expansionMarket Risk Summary & Daily Stock Trend Reports - Улправда
Stephens Initiates Coverage on Apogee Therapeutics With Overweight Rating, $95 Price Target - marketscreener.com
Stephens & Co. initiates coverage of Apogee Therapeutics (APGE) with overweight recommendation - MSN
How Apogee Therapeutics Inc. (APGE) Affects Rotational Strategy Timing - Stock Traders Daily
Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock - MarketBeat
Apogee Therapeutics Inc. $APGE Shares Sold by Braidwell LP - MarketBeat
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics CEO Sells 20,000 Shares - TradingView — Track All Markets
CEO Henderson Sells 20,000 ($1.5M) Of Apogee Therapeutics Inc [APGE] - TradingView — Track All Markets
Apogee Therapeutics (NASDAQ:APGE) Hits New 1-Year HighHere's Why - MarketBeat
Apogee Therapeutics Inc Stock (APGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Apogee Therapeutics Inc Stock (APGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Henderson Jane | Chief Financial Officer |
Dec 19 '25 |
Sale |
80.00 |
1,500 |
120,000 |
193,371 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):